The Global Small-Molecule APIs Market was valued at US$ 20.07 billion in 2021 and is predictable to reach US$ 53.79 billion by 2030 which is projected to attain a CAGR of 11.6 % during the forecast period from 2021- 2030.


The global small molecule API market is expected to rise due to the rising prevalence of diseases such as infections, cancer, and cardiovascular disorders during the forecast period. Furthermore, the expiration of patents on top-selling medications, as well as R&D and manufacture of small molecule APIs, are driving the market upwards during the forecast period.

A small molecule active pharmaceutical ingredient (API) is an organic substance with a molecular weight of less than 1 nm that aids in biological process regulation. The rate of generic medicine and small molecule API synthesis is increasing as a result of technological developments in the manufacturing sector.

Request for Sample Copy of this Research Report:

Increased frequency of diseases such as infections, cancer, and cardiovascular disease, is predicted to rise the global small molecule APIs market. Furthermore, increased public awareness of diseases and treatments, R&D activities for new medication development, improved healthcare facilities, and the rise of the elderly population are all contributing to the growth of the small molecule API market.

Stringent government regulations, financial crises, and a worldwide recession would all have a negative impact on market growth during the projected period. In addition, a shortage of experienced and trained healthcare staff, greater costs associated with small-molecule API, a large initial investment, and a lack of remuneration policy are all impeding market growth.

North America is leading the industry because of the rising frequency of chronic diseases and the great availability of modern technology and reimbursement policies in the region. The Asia Pacific region is expected to grow at a faster CAGR due to increased awareness of health care and the development of health infrastructure in the region during the forecast period.

Prominent players inducing the Global Small Molecule APIs Market are Lonza, Sun Pharmaceutical Industries Ltd., Pfizer Inc., Albemarle Corporation, BASF SE, Gilead Sciences Inc., Baxter International Inc., Celgene Corporation, Recipharm AB, Glenmark Pharmaceuticals Limited, AbbVie Contract Manufacturing, Bayer AG, CordenPharma International, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Aesica Pharmaceuticals Ltd., Cambrex Corporation, Gland Pharma Limited, AstraZeneca Plc, Boehringer Ingelheim International GmbH, Piramal Pharma Solutions, Evonik Industries AG, Siegfried AG, Aurinia Pharmaceuticals Inc., and Patheon among others.

Small Molecule APIs Market Segmentation:

By Product

  • Contract
  • Captive

By Type

  • Chemical Process
  • Biological Procedures

By Application

  • Cardiovascular
  • Dermatology
  • Urology
  • Ophthalmology
  • Metabolic
  • Respiratory
  • Others

By End-User

  • Ambulatory Surgical Centers
  • Hospitals
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America